Rome Therapeutics raises $77m for junk DNA-targeting drugs
pharmaphorum
SEPTEMBER 14, 2021
The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.
Let's personalize your content